Colorectal Cancer

New Protocol: Trifluridine-Tipiracil and Panitumumab for Refractory RAS WT Colorectal Cancer

2023-09-23

  • Study

    Phase II, multicenter (VELO)
    Patients with refractory RAS WT mCRC
    Trifluridine-tipiracil +Panitimumab (n=31) vs. Trifluridine-tipiracil (n=31)


  • Efficacy

    dCR of 4 month or more: 74.2% vs. 38.7%, p=0.009
    12mos PFS: 15.4 % vs 0%
    mPFS: 4.0 vs. 2.5 mos, HR:0.48, p=0.007

  • Safety

    Grade3 Aes: Rash (19% vs.0), neutropenia (26% vs.26%).


    • JAMA Oncol. 2023;9(7):966-970

    Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

    http://doi.org/10.1001/jamaoncol.2023.0655

    Reviewed by Elvin Chalabiyev, MD on Sep 23, 2023